Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6 ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in ...

Treatment Response with Tocilizumab Versus Placebo in Patients with Rheumatoid Arthritis According to the American College of Rheumatology (ACR) Criteria [20] Anthony Sebba, M.D., is Assistant ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for reducing the risk of cardiovascular problems in CKD who have ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the successful completion of the ...